Core Insights - He Eye Hospital, established in October 2009 and listed on the Shenzhen Stock Exchange in March 2022, is a prominent chain of ophthalmology medical services in China, leveraging advantages in brand, technology, and talent [1] Financial Performance - In Q3 2025, He Eye Hospital reported revenue of 855 million, ranking 11th among 15 companies in the industry, while the top competitor, Aier Eye Hospital, achieved revenue of 17.48 billion [2] - The net profit for the same period was 53.58 million, placing the company 7th in the industry, with Aier Eye Hospital leading at 3.367 billion [2] Financial Ratios - As of Q3 2025, He Eye Hospital's debt-to-asset ratio was 15.26%, down from 16.37% year-on-year, significantly lower than the industry average of 46.74% [3] - The gross profit margin for Q3 2025 was 41.83%, an increase from 40.92% year-on-year, exceeding the industry average of 31.10% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.55% to 9,888, while the average number of circulating A-shares held per account increased by 60.07% to 12,300 [5] - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund held 2.7015 million shares, a decrease of 93,200 shares from the previous period [5] Executive Compensation - The chairman and general manager, He Wei, received a salary of 1.1855 million in 2024, down from 1.3 million in 2023, reflecting a year-on-year decrease of 114,500 [4]
何氏眼科的前世今生：2025年三季度营收8.55亿低于行业均值，净利润5355.8万高于中位数